COST

1,017.71

-0.81%↓

PG

163.23

0%↓

KO

72.03

+0.06%↑

PM

170.5

+0.09%↑

PEP

131.83

-0.1%↓

COST

1,017.71

-0.81%↓

PG

163.23

0%↓

KO

72.03

+0.06%↑

PM

170.5

+0.09%↑

PEP

131.83

-0.1%↓

COST

1,017.71

-0.81%↓

PG

163.23

0%↓

KO

72.03

+0.06%↑

PM

170.5

+0.09%↑

PEP

131.83

-0.1%↓

COST

1,017.71

-0.81%↓

PG

163.23

0%↓

KO

72.03

+0.06%↑

PM

170.5

+0.09%↑

PEP

131.83

-0.1%↓

COST

1,017.71

-0.81%↓

PG

163.23

0%↓

KO

72.03

+0.06%↑

PM

170.5

+0.09%↑

PEP

131.83

-0.1%↓

Search

Compass Pathways Plc ADR

Open

3.9 -1.27

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

3.84

Max

3.95

Belangrijke statistieken

By Trading Economics

Inkomsten

25M

-18M

EPS

-0.419

Werknemers

166

EBITDA

-8.5M

-50M

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+371.11% upside

Dividenden

By Dow Jones

Volgende Winsten

31 jul 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-23M

366M

Vorige openingsprijs

5.17

Vorige sluitingsprijs

3.9

Technische score

By Trading Central

Vertrouwen

Bearish Evidence

Compass Pathways Plc ADR Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

4 feb 2025, 18:52 UTC

Belangrijke Marktbewegers

Psychedelic Drug Stocks Up, Vaccine Shares Down After Senate Committee Advances RFK Jr.

Peer Vergelijking

Prijswijziging

Compass Pathways Plc ADR Prognose

Koersdoel

By TipRanks

371.11% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 18.75 USD  371.11%

Hoogste 45 USD

Laagste 11 USD

Gebaseerd op 9 Wall Street-analisten die 12-maands prijsdoelen bieden voor Compass Pathways Plc ADR - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

9 ratings

9

Buy

0

Hold

0

Sell

Technische score

By Trading Central

3.645 / 4.0539Steun & Weerstand

Korte Termijn

Bearish Evidence

Gemiddeld Termijn

Strong Bullish Evidence

Lange Termijn

No Evidence

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Compass Pathways Plc ADR

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is headquartered in London, the United Kingdom.